ex vivo activated immune cells
Cell therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02169531)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T-lymphocytesImmunity, passive
T-lymphocytes immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ex vivo activated immune cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04837547 | Phase 1 | Sep 20, 2021 | Atrium Medical Corporation, University of Florida |
| NCT02169531 | Phase 1 | Mar 1, 2014 | B & Y Technologies, Guangzhou Medical University, The 12th People's Hospital of Shenzhen City |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atrium Medical Corporation | For profit | 1 | 0 | 1 | 2021 |
| B & Y Technologies | For profit | 1 | 1 | 1 | 2014 |
| Guangzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| The 12th People's Hospital of Shenzhen City | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1